Skip to main content
Erschienen in:

26.07.2022 | Case report

Two case reports of immune checkpoint therapy on chromophobe renal cell carcinoma with sarcomatoid differentiation

verfasst von: Takafumi Fukushima, Jun Teishima, Keisuke Goto, Kenshiro Takemoto, Yohei Sekino, Kohei Kobatake, Kenichiro Ikeda, Tetsutaro Hayashi, Kazuhiro Sentani, Naohide Oue, Takao Hinoi, Nobuyuki Hinata

Erschienen in: International Cancer Conference Journal | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Renal cell carcinoma (RCC) is the most predominant type of kidney cancer in adults and comprises several histological subtypes. Among them, the chromophobe RCC (ChRCC) with sarcomatoid differentiation is a rare subtype, and its therapeutic strategy remains unclear. Hence, to provide more information on effective therapeutic strategies against ChRCC, we report two cases of ChRCC with sarcomatoid differentiation treated with nivolumab monotherapy or ipilimumab–nivolumab combination therapy. One patient was treated with nivolumab monotherapy after the failure of sunitinib, while the other was treated with ipilimumab–nivolumab combination therapy as a first-line option. The therapeutic strategies adopted in both cases were effective, but the patients experienced immune-related adverse events such as interstitial nephritis and colitis. Thus, our report indicates that immune checkpoint therapy is effective for ChRCCs with sarcomatoid differentiation.
Literatur
1.
Zurück zum Zitat Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277–1290CrossRef Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277–1290CrossRef
2.
Zurück zum Zitat Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103–1115CrossRef Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103–1115CrossRef
3.
Zurück zum Zitat Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116–1127CrossRef Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116–1127CrossRef
4.
Zurück zum Zitat Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384(9):829–841CrossRef Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384(9):829–841CrossRef
5.
Zurück zum Zitat Motzer R, Alekseev B, Rha SY et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384(14):1289–1300CrossRef Motzer R, Alekseev B, Rha SY et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384(14):1289–1300CrossRef
6.
Zurück zum Zitat Ito K (2019) Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas. Int J Urol 26(9):868–877CrossRef Ito K (2019) Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas. Int J Urol 26(9):868–877CrossRef
7.
Zurück zum Zitat Casuscelli J, Becerra MF, Seier K et al (2019) Chromophobe renal cell carcinoma: results from a large single-institution series. Clin Genitourin Cancer 17:373–9.e4CrossRef Casuscelli J, Becerra MF, Seier K et al (2019) Chromophobe renal cell carcinoma: results from a large single-institution series. Clin Genitourin Cancer 17:373–9.e4CrossRef
8.
Zurück zum Zitat Moch H, Humphrey PA, Ulbright TM et al (2016) WHO classification of tumours of the urinary system and male genital organs, 4th edn. IARC, Lyon Moch H, Humphrey PA, Ulbright TM et al (2016) WHO classification of tumours of the urinary system and male genital organs, 4th edn. IARC, Lyon
9.
Zurück zum Zitat Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813CrossRef Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813CrossRef
10.
Zurück zum Zitat Keizman D, Sarid D, Lee JL et al (2016) Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib. Oncologist 21:1212–1217CrossRef Keizman D, Sarid D, Lee JL et al (2016) Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib. Oncologist 21:1212–1217CrossRef
11.
Zurück zum Zitat Armstrong AJ, Halabi S, Eisen T et al (2016) Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, openlabel, randomised phase 2 trial. Lancet Oncol 17:378–388CrossRef Armstrong AJ, Halabi S, Eisen T et al (2016) Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, openlabel, randomised phase 2 trial. Lancet Oncol 17:378–388CrossRef
12.
Zurück zum Zitat Koshkin VS, Barata PC, Zhang T et al (2018) Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer 6:9CrossRef Koshkin VS, Barata PC, Zhang T et al (2018) Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer 6:9CrossRef
13.
Zurück zum Zitat Chahoud J, Msaouel P, Campbell MT et al (2020) Nivolumab for the treatment of patients with metastatic non-clear cell renal cell carcinoma (nccRCC): a single-institutional experience and literature meta-analysis. Oncologist 25(3):252–258CrossRef Chahoud J, Msaouel P, Campbell MT et al (2020) Nivolumab for the treatment of patients with metastatic non-clear cell renal cell carcinoma (nccRCC): a single-institutional experience and literature meta-analysis. Oncologist 25(3):252–258CrossRef
15.
Zurück zum Zitat Ged Y, Chen YB, Knezevic A et al (2019) Metastatic chromophobe renal cell carcinoma: presence or absence of sarcomatoid differentiation determines clinical course and treatment outcomes. Clin Genitourin Cancer 17(3):e678–e688CrossRef Ged Y, Chen YB, Knezevic A et al (2019) Metastatic chromophobe renal cell carcinoma: presence or absence of sarcomatoid differentiation determines clinical course and treatment outcomes. Clin Genitourin Cancer 17(3):e678–e688CrossRef
16.
Zurück zum Zitat Pieretti AC, Westerman ME, Childs A et al (2021) Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol S1078–1439(21):00275–00281 Pieretti AC, Westerman ME, Childs A et al (2021) Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol S1078–1439(21):00275–00281
17.
Zurück zum Zitat Cheville JC, Lohse CM, Zincke H et al (2004) Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 28:435–441CrossRef Cheville JC, Lohse CM, Zincke H et al (2004) Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 28:435–441CrossRef
18.
Zurück zum Zitat Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794–5799CrossRef Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794–5799CrossRef
19.
Zurück zum Zitat Choueiri TK, Xie W, Kollmannsberger C et al (2011) The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 185(1):60–66CrossRef Choueiri TK, Xie W, Kollmannsberger C et al (2011) The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 185(1):60–66CrossRef
20.
Zurück zum Zitat Teishima J, Ohara S, Shinmei S et al (2018) Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival. Urol Oncol 36(7):339.e9-339.e15CrossRef Teishima J, Ohara S, Shinmei S et al (2018) Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival. Urol Oncol 36(7):339.e9-339.e15CrossRef
21.
Zurück zum Zitat Ohahi R, Angori S, Batavia AA et al (2020) Loss of CDKN1A mRNA and protein expression are independent predictors of poor outcome in chromophobe renal cell carcinoma patients. Cancers 12(2):465CrossRef Ohahi R, Angori S, Batavia AA et al (2020) Loss of CDKN1A mRNA and protein expression are independent predictors of poor outcome in chromophobe renal cell carcinoma patients. Cancers 12(2):465CrossRef
22.
Zurück zum Zitat Erlmeier F, Hartmann A, Autenrieth M et al (2016) PD-1/PD-L1 expression in chromophobe renal cell carcinoma: an immunological exception? Med Oncol 33:120CrossRef Erlmeier F, Hartmann A, Autenrieth M et al (2016) PD-1/PD-L1 expression in chromophobe renal cell carcinoma: an immunological exception? Med Oncol 33:120CrossRef
Metadaten
Titel
Two case reports of immune checkpoint therapy on chromophobe renal cell carcinoma with sarcomatoid differentiation
verfasst von
Takafumi Fukushima
Jun Teishima
Keisuke Goto
Kenshiro Takemoto
Yohei Sekino
Kohei Kobatake
Kenichiro Ikeda
Tetsutaro Hayashi
Kazuhiro Sentani
Naohide Oue
Takao Hinoi
Nobuyuki Hinata
Publikationsdatum
26.07.2022
Verlag
Springer Nature Singapore
Erschienen in
International Cancer Conference Journal / Ausgabe 4/2022
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-022-00561-y

Neu im Fachgebiet Onkologie

Körperlich fitte Krebskranke leben länger

Krebspatienten, auch und vor allem solche in fortgeschrittenen Stadien, profitieren offenbar von guter körperlicher Verfassung. Hohe Muskelkraft und kardiorespiratorische Fitness sind laut Ergebnissen einer Metaanalyse mit geringerer Mortalität assoziiert.

Kein (großer) Schutz vor Kolorektalkarzinom-Rezidiven durch ASS

Die erste Phase-3-Studie zum Nutzen von ASS in der adjuvanten Therapie des kolorektalen Karzinoms ist negativ verlaufen. Das abschließende Urteil über eine Sekundärprävention mit ASS ist trotzdem noch nicht gefallen.

Frühe CLL-Therapie: BTK-Hemmer verlängert EFS und PFS, aber nicht OS

Auch nach sechs Jahren ergibt sich kein Überlebensvorteil einer Therapie mit dem BTK-Hemmer Ibrutinib für Menschen mit frühem CLL-Stadium und erhöhtem Progressionsrisiko. Die Progressionsrate wird mit der Behandlung jedoch um über 80% gesenkt.

Adjuvantes Atezolizumab ohne Nutzen bei frühem TNBC

Patientinnen mit frühem triple-negativem Brustkrebs profitieren nach der Operation offenbar nicht von einer Zugabe des PD-L1-Hemmers Atezolizumab zur adjuvanten Standardchemotherapie. Die Studie, die das untersucht hat, wurde vorzeitig abgebrochen. Was könnte die schlechte Wirksamkeit erklären?

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.